|
End-of-day quote
Pakistan S.E.
2026-10-29
|
5-day change | 1st Jan Change | ||
| 326.01 PKR | +3.50% |
|
+3.98% | -16.36% |
Company Valuation: GlaxoSmithKline Pakistan Limited
Data adjusted to current consolidation scope
| Fiscal Period: December | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| Market Cap 1 | 126,403 | 124,132 | 103,824 | - | - |
| Change | - | -1.8% | -16.36% | - | - |
| Enterprise Value (EV) | 126,403 | 124,132 | 103,824 | 103,824 | 103,824 |
| Change | - | -1.8% | -16.36% | 0% | 0% |
| P/E | 19.3x | 12.4x | 9.82x | 8.16x | 7.27x |
| PBR | - | 3.69x | 2.72x | 2.31x | 2x |
| PEG | - | 0.2x | 1.78x | 0.4x | 0.6x |
| Capitalization / Revenue | - | 1.88x | 1.51x | 1.39x | 1.27x |
| EV / Revenue | - | 0x | 1.51x | 1.39x | 1.27x |
| EV / EBITDA | - | - | - | - | - |
| EV / EBIT | - | - | - | - | - |
| EV / FCF | - | - | - | - | - |
| FCF Yield | - | - | - | - | - |
| Dividend per Share 2 | - | 17 | 18.04 | 20.81 | 23 |
| Rate of return | - | 4.36% | 5.53% | 6.38% | 7.05% |
| EPS 2 | 20.52 | 31.48 | 33.21 | 39.96 | 44.85 |
| Distribution rate | - | 54% | 54.3% | 52.1% | 51.3% |
| Net sales 1 | - | 65,901 | 68,813 | 74,577 | 81,779 |
| EBITDA | - | - | - | - | - |
| EBIT | - | - | - | - | - |
| Net income 1 | 6,536 | 10,025 | 10,490 | 12,420 | 14,268 |
| Net Debt | - | - | - | - | - |
| Reference price 2 | 396.91 | 389.78 | 326.01 | 326.01 | 326.01 |
| Nbr of stocks (in thousands) | 318,467 | 318,467 | 318,467 | - | - |
| Announcement Date | 3/24/25 | 3/26/26 | - | - | - |
1PKR in Million2PKR
Estimates
P/E, Detailed evolution
| P/E (N) | EV / Sales (N) | EV / EBITDA (N) | Dividend Yield (N) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | 9.48x | - | - | 5.73% | 363M | |
| 37.84x | 13.27x | 28.43x | 0.53% | 1,148B | |
| 39.67x | 6.67x | 18.75x | 1.97% | 652B | |
| 37.4x | 8.39x | 17.35x | 2.4% | 505B | |
| 21.45x | 5.21x | 12.93x | 2.51% | 384B | |
| 102.73x | 5.76x | 24.72x | 2.42% | 348B | |
| 21.89x | 5.76x | 13.88x | 2.85% | 294B | |
| 22.21x | 4.49x | 12.82x | 1.97% | 264B | |
| 28.66x | 7.33x | 13.12x | 2.23% | 244B | |
| -45.79x | 7.11x | 27.55x | 2.07% | 197B | |
| Average | 27.56x | 7.11x | 18.84x | 2.47% | 403.75B | |
| Weighted average by Cap. | 35.28x | 8.40x | 20.64x | 1.79% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
Year-on-year evolution of the Yield
- Stock Market
- Stocks
- GLAXO Stock
- Valuation GlaxoSmithKline Pakistan Limited
Select your edition
All financial news and data tailored to specific country editions
